- /
- Supported exchanges
- / BA
- / MRK.BA
Merck & Company Inc (MRK BA) stock market data APIs
Merck & Company Inc Financial Data Overview
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Merck & Company Inc data using free add-ons & libraries
Get Merck & Company Inc Fundamental Data
Merck & Company Inc Fundamental data includes:
- Net Revenue: 65 011 M
- EBITDA: 29 105 M
- Earnings Per Share: 103 K
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-03
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Company Inc News
New
Merck’s KEYTRUDA Combo Wins and Pipeline Shuffle Might Change The Case For Investing In Merck (MRK)
In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based combinations and other pipeline assets across kidney, ovarian and bladder cancers,...
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s pharmaceu...
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
CHICAGO, March 03, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United St...
MXene Industry Research Report 2026: Market to Grow at a CAGR of 35.6% to 2032, Driven by EV & Charging Infrastructure, Water Treatment Applications and High-Performance Aerospace & Defense Systems
Company Logo The global MXene market, valued at USD 0.05 billion in 2026, is anticipated to reach USD 0.29 billion by 2032, experiencing a CAGR of 35.6%. The growth is driven by demand for high-perfo...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.